Reverie Labs Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2017

Location

Cambridge MA US

Primary Industry

Biotechnology

About

Based in Massachusetts, US, and founded in 2017, Reverie Labs, which operates as a pharmaceutical company develops deep learning-based modeling, massive-scale computation, and genetic algorithms to engineer new medicines. The company was co-founded by Jonah Kallenbach and Ankit Gupta and is backed by investors including Ridgeback Capital, Y Combinator, First Round Capital, and Neo. In February 2024, Ginkgo Bioworks acquired Reverie Labs from First Round Capital, Neo, Y Combinator, Ruvento Ventures, and Soma Capital Management. The company operates a drug discovery platform that uses computational chemistry and machine learning-technology to discover and develop kinase inhibitors. As of 2024, the company's product line has cancer-treating drugs such as RVL-101, RVL-1-2, and RVL-103, which are developed by partnering with other organizations such as Roche and Genentech

Current Investors

Y Combinator, Ruvento Ventures, Soma Capital Management

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Bioinformatics, Pharmaceutical Research & Development

Website

www.reverielabs.com

Verticals

Artificial Intelligence, Artificial Intelligence

Company Stage

Acquired

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.